A multicenter, randomized controlled clinical trial for the prevention of acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) with ruxolitinib
Latest Information Update: 03 Feb 2020
At a glance
- Drugs Ruxolitinib (Primary) ; Ciclosporin; Methotrexate; Mycophenolate mofetil
- Indications Graft-versus-host disease
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
Most Recent Events
- 03 Feb 2020 New trial record